Introduction
To date, over 200 monoclonal antibodies have passed through clinical testing in oncology (Reichert and Valge-Archer, 2007) , making them an accepted form of treatment for malignancy. A key mechanism of action for such antibodies is the killing of tumour cells through recruitment of the immune system, which is achieved through interaction of the Fc domains of complexed immunoglobulin G (IgG) with the complement component C1q or with FcgRs expressed on effector cells such as natural killer (NK) cells. In humans there are four principal Fcg receptors, the activating receptors, FcgRI, FcgRIIa, FcgRIIIa, and an inhibitory receptor, FcgRIIb. The majority of research into the activity of therapeutic antibodies has focused on the action of FcgRIIIa, whose expression is limited to NK cells. This focus stems, in part, from clinical studies in patients treated with Rituximab, in which patients homozygous for the F158 allotype of FcgRIIIa, which has a low affinity for monomeric IgG1, show reduced clinical responses relative to those carrying one or two allelles of the V158 allotype, which has a comparably higher affinity for the same ligand (Cartron et al., 2002; Weng and Levy, 2003) .
The part of the Fc region involved in FcgR binding was mapped, initially by binding studies and site-directed mutagenesis (Woof et al., 1986; Duncan et al., 1988; Canfield and Morrison, 1991; Lund et al., 1992; Shields et al., 2001) , to the C H 2 domain and the lower-hinge region, and subsequent crystal structures have validated these findings (Sondermann et al., 2000; Radaev et al., 2001) . A number of protein engineering strategies, including alanine scanning mutagenesis (Shields et al., 2001) , computer modelling (Lazar et al., 2006) and others (Dall'Acqua et al., 2006; Stavenhagen et al., 2007) , have been employed to identify variant Fcg1 regions that demonstrate improved binding to FcgRs; with the hope that such variants would confer greater clinical efficacy. Modification of the IgG carbohydrate side chains, which are essential to FcgR binding (Jefferis, 2007) , has been employed with similar aims, for example, through the absence of fucose residues, which increases affinity for FcgRIIIa (Niwa et al., 2004) .
Optimisation of defined protein attributes, e.g. proteinprotein interaction, can be achieved by a number of in vitro technologies including ribosome display. Ribosome display is a powerful in vitro display technology that can be used for the selection or directed evolution of proteins with specific function (Hanes et al., 1998; Jermutus et al., 2001; Amstutz et al., 2002; Thom et al., 2006) . This technology exploits cell-free translation to achieve coupling of phenotype and genotype by the production of stabilised ribosome complexes whereby translated proteins and their cognate mRNAs remain attached to the ribosome. Although ribosome display is a proven technology for evolving potency or affinity improvements in the Fab region of an IgG (Thom et al., 2006) , our aim in this study was to test the utility of the platform to engineer improved human Fcg1 (a homodimeric complex) binding to human FcgRIIIa. The affinity of aglycosylated Fcg1 for human FcgRIIIa is in the low millimolar range. Therefore, it was postulated that it would be difficult to achieve a stable complex for such a low-affinity interaction throughout the selection process.
Error-prone polymerase chain reaction (PCR) was used to generate a library of mutated Fcg1 regions, in a format appropriate for ribosome display, which then underwent directed selection, and in vitro screening, to identify Fcg1 regions with improved binding. We show here that after five rounds of increasingly stringent ribosome display selections, it was possible to identify a variant Fcg1, 125_B01, which demonstrated increased binding to FcgRIIIa. This increased binding translated to greater potency in vitro, in antibodydependent cellular cytotoxicity (ADCC) assays, using effector cells with both FcgRIIIa allotypes, V158, and in particular, F158. Characterisation of the mutations present in the Fcg1 region identified a single-point mutation at position 243, a carbohydrate contact residue that appears responsible for the increase in potency seen in FcgRIIIa-dependent assays, plausibly via alteration of the IgG1-Fc oligosaccharide profile.
Methods

Expression of human FcgR extracellular domains
Human FcgR extracellular domains (ECDs) were expressed and purified as described previously (Bonetto et al., 2009) . Briefly, PCR amplified sequences encoding the secretory signal of the extracellular domains of FcgRIIIaV158 and F158 were cloned into the pDEST12.2 oriP vector (Invitrogen, Paisley, UK) engineered to contain FLAG-and deca-His tags in frame with and 3' to the cloned gene. Vectors were transfected into HEK-EBNA cells using polyethyleneimine (Acros Organics, Morris Plains, NJ, USA) and subsequently cultured in Dulbecco's modified Eagle's medium containing 2% heat-inactivated foetal bovine serum and antibiotics. The medium was exchanged for serum-free CD-CHO medium 24 h after transfection and harvested after 3, 7 and 10 days, each time fresh media replaced the harvest. Secreted FcgR were purified using an Ä KTA TM Explorer (Amersham Pharmacia Biotech, Uppsala, Sweden). Crude extracts were passed over a 5 ml HisTrap TM HP column (Amersham Biosciences, Amersham, UK) at 5 ml/min, after which the column was washed with sodium phosphate buffer and NaCl (0.3 M, pH 7.2), followed by 10 column volumes of 16 mM and 40 mM imidazole in buffer. Subsequently protein was eluted with 20 column volumes of an imidazole gradient (40 -400 mM) in buffer. Fractions collected between 280 and 400 mM imidazole were analysed by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS -PAGE) on a Novex 4 -12% Bis-Tris gel (Invitrogen) and the purest fractions were pooled and concentrated using an Amicon Ultra-15 30 kDa filter (Amicon Millipore, Watford, UK). The resulting protein sample was buffer exchanged into phosphate-buffered saline (PBS) using a Superdex S75 HR 10/30 gel filtration column (Amersham Pharmacia Biotech, Amersham UK). Final protein concentrations were determined spectrophotometrically (280 nm), with purity assessed by SDS -PAGE and the molecular mass confirmed by MALDI-TOF/MS (Cyphergen Biosystems Ltd, Guilford, UK).
Creation of the ribosome display construct
The ribosome display DNA construct was assembled by PCR based on a method described previously (Hanes et al., 2000) .The final construct was comprised of a T 7 RNA polymerase promoter, a ribosome-binding site with the Shine-Dalgarno sequence, an open reading frame lacking a stop codon, and encoding for the lower hinge, C H 2 and C H 3 domains of Fcg1 (residues 224-447; Kabat and Wu, 1991) , together with a C-terminal spacer/tether sequence fused in-frame to the protein, comprising residues 130 -204 of the gene 3 coat protein of filamentous phage M13, which tethers the nascent protein to the ribosome while allowing sufficient distance for protein folding and interaction.
Random Fcg1 libraries
Error-prone PCR was performed on the human Fcg1 sequence by using the Diversify mutagenesis kit (Clontech Laboratories Inc., Palo Alto, CA, USA). PCR was performed in the presence of 640 mM MnSO 4 and either 40 mM or 200 mM dGTP to introduce an average of 4.6 or 8.1 mutations per kilobase of DNA, respectively. Individual mutations on variant 125_B01 were reverted back to their wild-type amino acid residue, either individually or in combination with other mutated residues, using site-directed mutagenesis (Quikchange, Stratagene, La Jolla, CA, USA).
Selections
Recombinant ECDs of FcgRIIIaV158 and F158 allotypes were biotinylated using biotin disulphide N-hydroxysuccinimide ester according to the supplier's instructions (Perbio/ Pierce, Rockford, IL, USA) and used in soluble ribosome display selections as described previously (Hawkins et al., 1992; Hanes et al., 2000) . In order to select for higheraffinity Fcg1 molecules, the initial concentration of FcgRIIIaV158 was kept below 1 mM, which was the lowest concentration at which a specific signal could be obtained for the wild-type Fcg1 using FcgRIIIaV158 allotype. Selections were initiated at 500 nM V158 allotype FcgRIIIa and then reduced gradually over five rounds of selection while maintaining binding to the F158 allotype of FcgRIIIa. A final round of selection against 10 nM protein A was carried out to preserve the ability to purify the IgG1-Fc variants. 125_B01 was selected using the following selection cascade: round 1, V158 at 500 nM; round 2, F158 at 500 nM; round 3, V158 at 500 nM; round 4, F158 at 250 nM and finally round 5, protein A at 10 nM.
Radioimmunoassay
Transcription and translation of selected Fcg1 variant mRNA was performed as described previously (Hanes et al., 2000) , in 96-well format, to generate [ 35 S]-methionine labelled Fcg1 variant proteins. Briefly, reverse transcriptase -PCR output was transcribed using a T7 Ribomax kit (Promega, Madison, WI, USA) and subsequently the mRNA purified on Sephadex G-25 SF (GE Healthcare, Bucks, UK) in 96-well plate format using a Multiscreen HTS assay system (Millipore Corp. Bedford, MA, USA). Translated products were bound to immobilised FcgRIIIaV158 or F158 allotypes (100 nM) in microtiter plastic plates (Nunc MaxiSorp, Life Technologies Ltd, Paisley, UK) for 2 h (room temperature) after which non-specifically bound translation products were washed away using three washes in PBS containing Tween 20 (0.4 mM), followed by three washes in PBS. Specifically bound translation products were eluted into scintillation fluid using triethylamine (100 ml, 0.1 M) and quantitated using a TopCount.NXT scintillation microplate counter (PerkinElmer Inc., Waltham, MA, USA). Improved binders were identified by comparison with wild-type [
35 S]-Met labelled Fcg1, confirmed by repeated assay. Variant Fcg1 domains having improved binding were subcloned into pUC119, an Escherichia coli expression vector possessing a C-terminal FLAG tag and Ampicillin resistance. All cloned variants were subsequently sequenced.
Expression of wild-type and variant Fcg1 and IgG1
Fcg1 variant and wild-type bearing a poly-His tag were expressed in E.coli by induction with isopropyl b-D-thiogalactoside, and subsequently isolated from the periplasm by Ni 2þ -nitrilotriacetic acid chromatography, as described previously (Vaughan et al., 1996) . Human IgG1 antibody bearing Rituximab or 1.5.3 variable domains were cloned into the human IgG1 pEU expression vectors (Persic et al., 1997) . Co-transfection of the heavy-chain vector and k light-chain vector into HEK EBNA-293 cells allowed IgG1 to be expressed and purified by protein A affinity chromatography (GE Healthcare). Human IgG1 bearing the 125_B01 Fc region was created by directional cloning of the Fcg1 mutant gene into the heavy-chain vector; replacing the wildtype Fcg1 DNA. Protein concentrations of Fcg1 and IgG1 were determined using the bicinchoninic acid assay.
Alpha Screen w ligand inhibition assay as a secondary screen
His-tagged recombinant FcgRIIIaV158 (or FcgRIIIaF158) protein was pre-incubated with nickel chelate acceptor beads, thus generating FcgRIIIa-acceptor bead complexes. In parallel, biotinylated aglycosylated human IgG1 was preincubated with streptavidin donor beads to facilitate donor bead capture of aglycosylated hIgG1. (The aglycosylated IgG1 was generated by performing a T299A residue replacement within the Fcg1 region of the IgG.) A ligand inhibition assay was executed such that the homodimeric aglycosylated Fcg1 variant protein preparations were added to the FcgRIIIa-acceptor bead complexes for a further 30-min incubation step, followed by addition of the aglycosylated IgG1-donor bead complexes for a final incubation of 1 h. Luminescence generated in the Alpha Screen w assay was then measured on a Fusion-a microplate analyser (PerkinElmer Biosignal, Montreal, QC, Canada); effectively, the interaction between the IgG1 and FcgRIIIa was inhibited by addition of increasing concentrations of the homodimeric Fcg1 variant.
ADCC assay
Peripheral blood mononuclear cells (PBMCs) were recovered from human blood by layering over Ficoll-paque (GE Healthcare) and centrifuging at 400g for 40 min. PBMCs were washed twice in PBS and NK cells were purified by negative selection using Robosep and the human NK cell enrichment kit (Stem Cell Technologies Inc., Vancouver, Canada) as per the manufacturer's instructions. FcgRIIIa allotyping of purified NK cells was performed by flow cytometry as described previously (Bottcher et al., 2005) .
Daudi cells (5 Â 10 3 ) obtained from ECACC (Salisbury, UK) were incubated at 378C for 2 h together with antibody and NK effector cells at the effector to target (E:T) ratios indicated, in RPMI 1640 Glutamax I (Invitrogen) supplemented with 10% foetal bovine serum having low levels of endogenous IgG and 1% penicillin/streptomycin. Wells that contained target cells alone were lysed completely by the addition of 10 ml of lysis agent (Cell Technology Inc., Mountain View, CA, USA) 15 min before the end of incubation. Supernatant (100 ml) was transferred to a 96-well Optiplate (PerkinElmer) and assayed for glyceraldehyde 3-phosphate dehydrogenase levels using the aCella-Tox kit (Cell Technology Inc.) as per the manufacturer's instructions. All wells were corrected for background contributions from the medium and the percentage lysis in each well was calculated as follows: 
Oligosaccharide analysis
Oligosaccharide analysis was carried out by the National Institute for Bioprocessing Research and Training (NIBRT, Dublin, Ireland) on wild-type and 125_B01 a-CD20 IgG1 antibodies. Briefly, following SDS-PAGE oligosaccharides were released from the IgG heavy chain by enzymatic digestion with PNGaseF, derivatised with the fluorescent reagent 2-aminobenzamide and analysed for mobility by normal phase high-performance liquid chromatography (NP-HPLC) on a GlycoSep N column (4.6 mm Â 250 mm), relative to known oligosaccharide standards as documented in the GlycoBase online database (Campbell et al., 2008) . Due to the significant levels of sialylated oligosaccharides found in sample 125_B01 (Fig. 4 and Table I ), these oligosaccharides were first fractionated on the basis of charge by weak anion-exchange (WAX)-HPLC. Subsequent identification was by NP-HPLC analyses of the fractions following additional exoglycosidase digestion with bovine kidney fucosidase (specific for release of a1,6 linked fucose) and almond meal fucosidase (specific for a1,3 & a1,4 linked fucose), and arthrobacter ureafaciens sialidase (specific for release of a2,3 & a2,6 sialic acids) and streptococcus pneumoniae sialidase (specific for a2,3 sialic acids). 
Results
Fcg1 maturation using ribosome display
Ribosome display was used to display a monomeric Fcg1 consisting of residues 224-447 of the human IgG1 heavy chain. These monomeric regions are likely to favour dimerisation upon display, via extensive non-covalent interactions in the C H 3 region and covalent disulphide bridge formation between the two cysteine residues within each hinge peptide sequence. Randomised Fcg1 libraries were created by errorprone PCR amplification of Fcg1 DNA prior to the initial round of selection. Ribosome display was performed by using decreasing concentrations of FcgRIIIa, reduced progressively from 500 nM FcgRIIIa (V & F158 allotypes) over five rounds of selection, followed by a final round of selection against protein A in order to preserve the ability to purify protein at a later stage. Analysis of the selection products, quantitated by end-point PCR, confirmed enrichment of the library for FcgRIIIa binding (Fig. 1a) when compared with wild-type Fcg1 (Fig. 1b) , demonstrating that ribosome display can be used to affinity mature an Fc region.
Identification of 125_B01 Fcg1 by in vitro screening
The enriched library of Fcg1 variants resulting from ribosome display selections was screened by radioimmunoassay in a 96-well format, for individual variants including 125_B01 that showed improved binding to FcgRIIIaV158 when compared with wild-type Fcg1 (n ¼ 2, improved by at least 30%). All variants with improved binding were cloned and expressed in E.coli. These aglycosylated, bacterially produced, Fcg1 regions were then tested, in a ligand inhibition assay using Alphascreen w , for their ability to inhibit the interaction between FcgRIIIaV158 and an aglycosylated IgG1. A number of variants demonstrated improved binding to FcgRIIIaV158, including variant 125_B01 that, unlike the wild-type, was able to inhibit aglycosylated IgG1:FcgRIIIaV158 recognition when in soluble form (Fig. 2a) . Sequence analysis of 125_B01 showed that it possessed three mutations from that of the wild-type sequence, namely F243L, T393A and H433P. Improved variants, including 125_B01, were cloned into pEU vectors for expression as full-length human IgG1 in HEK-EBNA cells. Subsequent functional assays demonstrated improved binding of variant 125_B01 to both FcgRIIIa allotypes as a fully glycosylated a-CD20 IgG1 antibody, plausibly due to an altered oligosaccharide profile relative to the wild-type IgG1 that is discussed in detail within the section on oligosaccharide. The 125_B01 IgG1 variant results in increased potency and reduced discrimination between different FcgRIIIa allotypes relative to wild-type IgG1
The functional consequences of the improved FcgRIIIa affinity seen for the 125_B01 variant were tested in vitro using an ADCC assay. The Daudi B-cell line, which expresses CD20, was sensitised by addition of the a-CD20 antibody Rituximab bearing either the 125_B01 variant or a wild-type IgG1 Fcg domain, and subsequently assessed for ADCC mediated by primary human NK cells (Fig. 2b) . As in previous studies, the level of lysis seen with antibodies bearing wild-type IgG1 varied depending on the FcgRIIIa allotype of the NK cells used, such that those cells homozygous for the V158 form of the receptor gave an EC 50 around three times smaller than that seen with donors homozygous for the F158 form of the receptor. Variant 125_B01 IgG1 triggered an increased level of lysis relative to wild-type IgG1, with the difference in lysis being more pronounced for F158 donors. In donors bearing the F158 form of the receptor variant 125_B01 resulted in a maximum level of lysis that was two-fold greater than seen with wild-type IgG1 (45% versus 23%) and an EC 50 that was four-fold reduced (0.15 versus 0.64 nM). For V158 donors the increase in maximal lysis was only 1.3-fold greater (42% versus 34%) and the reduction in EC 50 only 3.5-fold relative to wild type. The effect of this biased increase in potency is an IgG1-Fc that shows overall increases in potency across all NK cell donors, but which additionally reduces the differences between donors bearing FcgRIIIa of a different allotype.
The increase in potency seen with 125_B01 can be attributed primarily to an F243L mutation Sequencing of the 125_B01 variant revealed three amino acid residue differences from the wild-type Fcg1, namely F243L, T393A and H433P (Fig. 3a) . None of these three residues lies within the section of the Fcg1 region that directly contacts FcgRIIIa, and so, to gain greater insight into their individual roles, each of the three point mutations was reverted to wild-type by site-directed mutagenesis. This resulted in a set of three mutant IgG1-Fc antibodies each containing only two-point mutations. Rituximab antibodies bearing these Fcg1 regions were examined for their ability to trigger lysis of Daudi cells in an ADCC assay relative to one another, and to the previously characterised S298A/E333A/ K334A (SEK) triple mutant Fcg1 domain (Shields et al., 2001) (Fig. 3b) . The 125_B01 variant Fcg1 domain resulted, as before, in an increased potency with respect to ADCC. However, reversion of the mutation at either position 433 or 393 had little or no effect on the activity of the 125_B01 variant, while in contrast reversion of the leucine at position 243 to the wild-type phenylalanine residue resulted in complete loss of any potency increase seen relative to a wild-type Fcg1 (blue circle) or 125_B01 revertants in which one of the three mutations had been reverted to wild-type; 243_rev (diamond), 393_rev (inverted triangle) and 433_rev (triangle). Subsequently, the cells were incubated with human NK cells (taken from a donor homozygous for the F158 FcgRIIIa allotype), at an effector:target ratio of 25:1. The level of ADCC, measured via release of GAPDH after 2 h, was greater when the target cells were sensitised with the 125_B01 variant, this increase in ADCC was negated by reversion of the mutation at residue 243. (c) Mutation at position 243 alone is sufficient for enhanced ADCC. Daudi cells were sensitised by addition of 1.5.3 a-CD20 IgG1 having wild-type Fcg1 (diamond), or an Fcg1 domain carrying a single mutation at position 243 (circle), Rituxan a-CD20 IgG1 with wild-type Fcg1 domain (square) was included for comparison. Subsequently, the cells were incubated with human NK cells (taken from a donor homozygous for the F158 FcgRIIIa allotype), at an effector:target ratio of 25:1. The level of ADCC, measured via release of GAPDH after 2 h, was greater when target cells were sensitised with the 1.5.3 a-CD20 relative to Rituxan, and this was further enhanced by inclusion of the mutation at residue 243.
IgG1-Fc. This indicated that the 243L mutation was predominantly responsible for the increase in FcgRIIIa binding seen with the variant 125_B01. In order to confirm this, a variant Fcg1 domain containing only the mutation at position 243 was combined with a previously characterised alternative a-CD20 variable domain, 1.5.3 (Bornstein et al., 2010) . This single-point mutation variant was examined for its ability to trigger ADCC relative to the 1.5.3 antibody carrying a wildtype Fcg1 domain and the Rituximab antibody used in previous experiments (Fig. 3c) . As previously observed the 1.5.3 a-CD20 triggers slightly increased ADCC relative to Rituximab, and as expected based on the reversion analysis, the single-point mutation at position 243 is sufficient to enhance this level of ADCC further.
Oligosaccharide analysis of wild-type and 125_B01 a-CD20
IgG1 antibodies
The complex oligosaccharide attached to Asn-297 of IgG-Fc is known to modulate recognition by effector ligands and consequently effector functions. While the 125_B01 variant demonstrated improved receptor binding even when aglycosylated, the 243 residue lies within the region of the C H 2 domain involved in these carbohydrate interactions, raising the possibility that changes in carbohydrate may additionally contribute to the increased potency seen for this variant. In order to explore this possibility further, the oligosaccharide profiles of both the 125_B01 and wild-type IgG1 antibodies were analysed by NP-HPLC (Fig. 4) , and the quantitative oligosaccharide data are summarised in Table I . It is evident that 125_B01 oligosaccharides have increased levels of galactose, bisecting N-acetylglucosamine and sialylation, with increased levels of afucosylated oligosaccharide chains relative to the wild-type. While the addition of 20% afucosylated IgG to wild type was able to enhance the level of ADCC similarly to 125_B01 (data not shown), a functional contribution from other oligosaccharide residues such as bisecting N-acetylglucosamine cannot be ruled out.
Discussion
Ribosome display selections on IgG1-Fc heavy chains and subsequent expression of IgG variants in mammalian cells has for the first time demonstrated that it is possible to generate glycosylated IgGs with modified activity in ADCC assays. In particular a variant 125-B01 that comprises three separate residue replacements, F243L within the CH2 domain, and T393A and H433P within the CH3 domain. From the co-crystal structure of Fcg1 in complex with FcgRIII (Sondermann et al., 2000) it seems plausible that the F243L replacement within the A strand may effect a local structural change, able to influence FcgRIIIaV158 binding significantly to this strand. However, the other two replacements T393A and H433P within the CH3 domain may also contribute to improved recognition, due to their proximity ( 10Å ) to the CH3 -CH3 and CH2 -CH3 domain interfaces, respectively. FcgRI recognition was similarly reported to be modulated indirectly by replacements within the CH3 domain that included a replacement M428I located at the CH2 -CH3 interface (Jung et al., 2010) . Generally, the majority of replacements found to affect receptor binding tend to be within, or proximal to, the binding sites on IgG-Fc that include the lower hinge for the FcgR, or the CH2 -CH3 interface for FcRn (Shields et al., 2001) .
Comparison of the oligosaccharide profiles of variant 125_B01 relative to wild type revealed an increased level of afucosylated oligosaccharide chains in 125_B01, shown previously to enhance binding to FcgRIIIa and subsequent ADCC activity (Shields et al., 2002; Niwa et al., 2004) . Fucosylated oligosaccharide chains on IgG1-Fc have been proposed to sterically hinder binding to FcgRIIIa via interaction with its own oligosaccharide moieties attached at Asn-162 (Ferrara et al., 2006) . A corollary of this proposal is that differences in oligosaccharide profiles at Asn-162 may modulate IgG recognition, for example between the HEK-EBNA derived soluble receptor used for binding and selection studies, and receptor expressed on human NK cells used for ADCC assays. In the case of IgG having one or more afucosylated oligosaccharide chains, the receptor oligosaccharide can make energetically favourable interactions with the Fc CH2 domain leading to an increased affinity for the complex. In addition to differences seen in the extent of fucosylation found for 125-B01 oligosaccharides, there is an increased level of oligosaccharides bearing bisecting N-acetylglucosamine (Umana et al., 1999) , sialic acid (Jassal et al., 2001) and two galactose residues that could each contribute to enhanced function. It is noted that the oligosaccharide profile will vary depending on the cell line used for expression. For example, the CHO cell line lacks GlcNAc transferase III and consequently oligosaccharides with bisecting GlcNAc or the ability to carry out a-2,6 sialylation (Lund et al., 1996 , Jassal et al., 2001 .
It is plausible that, based on the altered oligosaccharide profile found for variant 125_B01, replacement of residue Phe-243 by Leu within the oligosaccharide interaction site of the C H 2 domain alters recognition by oligosaccharideprocessing enzymes, as was inferred for an alanine replacement at residue 243 in the case of a human IgG3 expressed in CHO cells (Lund et al., 1996) . The resultant altered oligosaccharide profile correlates with enhanced recognition of variant 125_B01 by FcgRIIIa and increased ADCC relative to wildtype IgG1. Such a variant IgG1-Fc could confer benefit in a clinical setting by showing increased efficacy relative to wildtype IgG1, due to its greater potency, but also by reducing variability in response within the patient population.
